Clinical Trials
10 trialsNCT05564377 2026-05-27
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05615818 2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT05372614 2026-05-18
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
NCT06126276 2026-05-13
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04502602 2026-05-11
iNNOVATE
Virginia Commonwealth University
Phase 1 Active not recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT04374305 2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2 Recruiting
NCT03919292 2026-04-21
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Virginia Commonwealth University
Phase 1/2 Recruiting
NCT03377387 2026-04-16
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT04886531 2026-04-08
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Phase 2 Recruiting